CXCL9 and COVID-19: In line with reduced IFN-γ, we found markedly lower levels of CXCL9 (an IFN-γ-induced chemokine) in COVID-19 critical patients compared to MAS, indicative of decreased type II interferon signalling (Fig. 1a).